VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
This Quarter Return
-5.48%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$97.2M
AUM Growth
+$97.2M
(-16%)
Cap. Flow
+$17.2M
Cap. Flow
% of AUM
17.74%
Top 10 Holdings %
Top 10 Hldgs %
76.66%
Holding
55
New
10
Increased
17
Reduced
2
Closed
8
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$8.32M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$2.86M |
| 3 |
Zevra Therapeutics
ZVRA
|
$2.73M |
| 4 |
scPharmaceuticals
SCPH
|
$2.41M |
| 5 |
Mineralys Therapeutics
MLYS
|
$2.39M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$4.36M |
| 2 |
Nurix Therapeutics
NRIX
|
$1.84M |
| 3 |
Kura Oncology
KURA
|
$1.31M |
| 4 |
Rezolute
RZLT
|
$1.16M |
| 5 |
Collegium Pharmaceutical
COLL
|
$822K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$207M
| $15.4M | 15.81% | 6,986,744 | – | – |
|
|
SLRN
2
DELISTED
ACELYRIN
SLRN
| $8.32M | 8.56% | +3,366,945 | New | +$8.32M |
|
|
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
| $8.19M | 8.42% | 185,520 | – | – |
|
4
Protara Therapeutics
TARA
$120M
| $7.1M | 7.31% | 1,667,800 +88,800 | +6% | +$378K |
|
|
5
Praxis Precision Medicines
PRAX
$958M
| $7.01M | 7.21% | 185,000 -115,000 | -38% | -$4.36M |
|
6
Tourmaline Bio
TRML
$601M
| $6.93M | 7.13% | 455,412 +31,617 | +7% | +$481K |
|
7
Jasper Therapeutics
JSPR
$45.5M
| $6.17M | 6.34% | 1,433,828 | – | – |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $6.03M | 6.2% | 95,000 +45,000 | +90% | +$2.86M |
|
|
9
Zevra Therapeutics
ZVRA
$509M
| $4.98M | 5.12% | 665,000 +365,000 | +122% | +$2.73M |
|
10
Liquidia Corp
LQDA
$2.38B
| $4.43M | 4.55% | 300,000 | – | – |
|
11
InspireMD
NSPR
$102M
| $2.43M | 2.5% | 904,029 | – | – |
|
|
12
scPharmaceuticals
SCPH
$295M
| $2.41M | 2.48% | +917,668 | New | +$2.41M |
|
|
13
Mineralys Therapeutics
MLYS
$1.03B
| $2.39M | 2.46% | +150,600 | New | +$2.39M |
|
14
Replimune Group
REPL
$422M
| $1.78M | 1.83% | 182,083 +716 | +0.4% | +$6.98K |
|
15
Edesa Biotech
EDSA
$16.3M
| $1.68M | 1.73% | +687,500 | New | +$1.68M |
|
16
Instil Bio
TIL
$182M
| $1.2M | 1.23% | +69,000 | New | +$1.2M |
|
|
17
Rezolute
RZLT
$619M
| $1.16M | 1.19% | 400,000 -400,000 | -50% | -$1.16M |
|
18
Eledon Pharmaceuticals
ELDN
$155M
| $1.1M | 1.13% | 323,973 | – | – |
|
19
Perspective Therapeutics
CATX
$250M
| $1.07M | 1.1% | 500,000 | – | – |
|
20
Geron
GERN
$893M
| $1.04M | 1.07% | 655,000 +606,000 | +1,237% | +$964K |
|
21
Immunome
IMNM
$828M
| $1.03M | 1.06% | +153,500 | New | +$1.03M |
|
22
TELA Bio
TELA
$70.5M
| $912K | 0.94% | +747,410 | New | +$912K |
|
23
Avalo Therapeutics
AVTX
$122M
| $897K | 0.92% | 111,972 +2,000 | +2% | +$16K |
|
24
Sutro Biopharma
STRO
$72.7M
| $670K | 0.69% | 1,030,000 +1,000,000 | +3,333% | +$651K |
|
|
UPB
25
Upstream Bio, Inc. Common Stock
UPB
$923M
| $655K | 0.67% | +107,000 | New | +$655K |
|